Immunotherapeutics at the spearhead: current status in targeting neuroendocrine neoplasms.

Immunotherapeutics are gaining a post in the field of NENs in cases progressing during the course of the disease, dictating urgently the identification of biomarkers that will enable selection of NEN patients who may benefit from this treatment.